70415-89-3

Upstream product

• 116-17-6 triisopropyl phosphite 
• 16671-77-5 3-nitrophenyl thiocyanate 
• 99-65-0 meta-dinitrobenzene 
• 20607-43-6 sodium isopropanethiolate 
• 537-91-7 bis(3-nitrophenyl) disulfide 
• 75-26-3 isopropyl bromide 

Downstream Products

• 80213-20-3 1-nitro-3-(propane-2-sulfonyl)benzene 
• 170856-37-8 3-(propan-2-ylsulphonyl)aniline 
• 1097922-05-8 4-chloro-N-[3-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine 
• 1097920-31-4 N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[3-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

Discovery of N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a potent and selective anaplastic lymphoma kinase (ALK) inhibitor

Anaplastic lymphoma kinase (ALK) is a validated therapeutic target for treating echinoderm microtubule- associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer (NSCLC). We synthesized a series of 1,3,5-triazine derivatives and identified ASP3026 (14a) as a potent and selective ALK inhibitor. In mice xenografted with NCI-H2228 cells expressing EML4-ALK, once-daily oral administration of 14a demonstrated dose-dependent antitumor activity. Here, syntheses and structure-activity relationship (SAR) studies of 1,3,5-triazine derivatives are described.